US Earnings Financial Results SEC Filings — June 01, 2026

01-06-2026

01-06-2026

Freedom Holding Corp. reported total revenue of $2.19B for fiscal 2026, up 9% from $2.00B in fiscal 2025, driven by a strong recovery in trading securities (net gain of $158.8M vs. a $57.8M loss last year) and growth in interest income (+2%) and sales of goods and services (+143%). However, net insurance revenue declined sharply by 30% to $402.4M, and fee and commission income fell 3% to $489.8M, reflecting mixed performance across segments.

• · Interest income on trading securities dropped 50% YoY to $191.0M, while interest income on loans to customers grew 37% to $283.7M and margin loans grew 31% to $277.6M.
• · Net gain on trading securities swung from a $57.8M loss in FY2025 to a $158.8M gain in FY2026, driven by a $164.0M realized gain partially offset by a $5.1M unrealized loss.
• · Net insurance revenue fell 30% to $402.4M, with written premiums down 24% to $507.3M and deferred profit liability issuance expense up 74% to $88.3M.
• · Sales of goods and services surged 143% to $97.4M, and net gain on derivatives rose 438% to $66.8M.
• · Interest income on held-to-maturity securities increased from $1.0M to $49.7M, reflecting a shift in asset allocation.
• · Average balance of trading securities declined to $1.71B from $3.15B, while average loans issued grew to $1.83B from $1.41B.
• · The rate/volume analysis shows that the $43.9M increase in total interest income was primarily volume-driven ($35.6M) versus rate-driven ($10.8M).

01-06-2026

Universal Corp reported a challenging fiscal year ended March 31, 2026, with consolidated sales declining 1% to $2,924.5M and operating income falling 28% to $168.5M, driven by a $41.1M goodwill impairment and a 74% plunge in Ingredients operating income to $3.2M. Adjusted diluted EPS dropped 43% to $2.64, while net debt rose to $845.5M and net debt/net capitalization increased to 37%. However, the company reduced SG&A expenses by 2% and significantly lowered restructuring costs by 83%.

• · Goodwill impairment of $41.1M was recorded in FY2026, compared to none in FY2025.
• · Total debt decreased to $904.3M as of March 31, 2026 from $1,072.9M a year earlier, primarily due to a reduction in notes payable and overdrafts.
• · Net debt/net capitalization (non-GAAP) edged up to 37% from 36%.
• · Total shareholders' equity declined to $1,461.1M from $1,500.5M.
• · Total assets decreased to $2,766.8M from $2,989.6M.
• · Inventory purchase obligations for tobacco total $857.3M, with $698.5M due within one year.
• · Interest expense decreased to $74.0M from $79.6M.
• · Equity in pretax earnings of unconsolidated affiliates fell to $3.4M from $9.1M.
• · Pension settlement charge of $14.1M was recorded in FY2025 but none in FY2026.
• · Other comprehensive income was $6.4M in FY2026 vs. $1.1M in FY2025.

01-06-2026

ProPhase Labs, Inc. filed its 2025 10-K, reporting a net loss improvement to $14.7M from $53.3M in 2024, driven by a significant reduction in operating losses and gain from discontinued operations. Revenue declined 35.8% to $4.3M, but gross profit turned positive at $1.4M versus a prior loss. The company raised $6.9M in financing activities and reduced its cash position to $0.09M, while total assets fell slightly to $59.9M.

• · Adjusted EBITDA from continuing operations improved to -$6.9M in 2025 from -$17.9M in 2024.
• · Debt extinguishment gain of $0.8M and employee retention tax credit income of $2.3M boosted 2025 results.
• · Cash used in operating activities (continuing) was -$8.9M in 2025 vs -$11.8M in 2024.
• · The company recognized a $43.7M investment in unconsolidated affiliates and deconsolidated $16M in assets/liabilities.
• · Accounts payable to unconsolidated affiliates stood at $27.6M at year-end 2025, compared to zero in 2024.
• · Total current liabilities surged to $53.1M from $32.1M, driven by the affiliate payables and increased short-term debt.
• · Accumulated deficit widened to -$73.1M from -$58.4M.
• · Weighted average basic shares outstanding increased dramatically to 8.5 million from 2.0 million, reflecting significant dilution.

01-06-2026

Greenwich LifeSciences, Inc. (GLSI) filed its Form 10-K annual report for the fiscal year ended [not specified], highlighting that it is a clinical-stage biopharmaceutical company with no current source of revenues and a history of substantial losses. The company expects to continue incurring substantial and increasing losses for the foreseeable future, primarily due to ongoing clinical trials for its lead product candidate, GP2, and other development activities. The filing also notes a material uncertainty about the company's ability to continue as a going concern, as it will need to raise substantial additional capital to fund operations.

• · The company has no source of revenues and may never generate revenues or achieve profitability.
• · The company expects to continue incurring substantial and increasing losses for the foreseeable future.
• · The filing includes a going concern warning, indicating the need to raise substantial additional capital.
• · The company's lead product candidate is GP2, an immunotherapy for breast cancer.
• · The company faces risks related to clinical trial success, regulatory approval, commercialization, and competition.
• · The company relies on third parties for clinical trials, manufacturing, and supply.
• · The company has not yet established sales, marketing, or distribution capabilities.
• · The company's ability to obtain regulatory approvals and market acceptance is uncertain.
• · The company is exposed to risks from operating in foreign countries, including regulatory, economic, and geopolitical factors.
• · Healthcare cost reduction legislation could materially adversely affect the company's business.

01-06-2026

Mountain Crest Acquisition 6 Corp. reported its first quarterly results since inception on January 6, 2026, through March 31, 2026. The SPAC had not yet completed an IPO or business combination, generating no revenue and recording a net loss of $43,470 from formation and administrative costs. As of March 31, 2026, the company held $30,000 in cash, had total assets of $116,950, and was in a shareholder's deficit position of $18,470, with $95,420 owed under a related-party promissory note.

• · Basic and diluted net loss per ordinary share was $(0.02) for the period.
• · Formation costs of $3,050 were paid by the Sponsor in exchange for issuance of ordinary shares.
• · Deferred offering costs of $40,000 are included in accrued offering costs.
• · Deferred offering costs of $21,950 were paid by the Sponsor in exchange for issuance of ordinary shares.
• · Proceeds of $95,420 from a related-party promissory note were the primary source of financing.
• · Payment of deferred offering costs of $25,000 was a financing use of cash.
• · No preference shares were issued or outstanding.
• · The company had zero beginning cash balance (inception on January 6, 2026).

01-06-2026

Boost Run Inc. (BRUN) reported a net loss of $51,000 for the three months ended March 31, 2026, compared to an accumulated deficit of $51,450 at year-end 2025, indicating continued losses. Total assets surged to $264,098 from $77,434, driven by large increases in operating and finance lease right-of-use assets, while total liabilities rose to $259,882 from $69,298. However, the company's accumulated deficit deepened to $102,450 from $51,450, and total members' capital fell to $4,216 from $8,136, reflecting a deteriorating equity position.

• · Net loss per share (basic and diluted) was $51,000 for Q1 2026.
• · Weighted average common stock outstanding was 1 share.
• · Cash provided by operating activities was $0 for Q1 2026.
• · Cash used in investing and financing activities was $0 each.
• · Related party payable increased by $26,000 and accrued expenses increased by $25,000 during Q1 2026.
• · Deferred transaction costs rose to $1,662 from $1,002.
• · Prepaid expenses decreased to $3,428 from $6,187.
• · Other current assets increased to $632 from $131.
• · Credit card payable decreased to $174 from $222.
• · Operating lease liabilities (current) rose to $12,435 from $4,388.
• · Finance lease liabilities (current) rose to $38,147 from $12,721.
• · Accrued expenses and other liabilities (current) rose to $23,481 from $16,661.
• · Related party loan (current) was $1,430 at March 31, 2026, versus $0 at December 31, 2025.
• · Accrued expenses and other liabilities (non-current) were $19,614 at March 31, 2026, versus $0 at December 31, 2025.
• · Operating lease liabilities (non-current) rose to $89,696 from $4,971.
• · Finance lease liabilities (non-current) rose to $48,635 from $17,664.
• · Related party loan (non-current) was $0 at March 31, 2026, versus $1,430 at December 31, 2025.
• · Debt (non-current) was $0 at March 31, 2026, versus $4,594 at December 31, 2025.
• · Members' interests remained unchanged at $11,182.
• · Additional paid-in capital increased to $14,191 from $13,993.
• · Capitalized software decreased to $250 from $276.
• · Intangible assets remained unchanged at $16.

01-06-2026

Bridgford Foods reported a net loss of $4.9M for the 12 weeks ended April 17, 2026, widening from a $3.9M loss in the prior-year period, as gross margin fell sharply to $8.8M from $11.1M. Net sales declined 1.2% to $50.0M, while operating loss deepened to $5.8M from $3.2M. However, cash used in operations improved to $1.8M from $5.4M in the prior-year period, and the company drew $3.3M from its revolving credit facility to support liquidity.

• · Walmart accounted for 28.6% of sales and 6.0% of accounts receivable as of April 17, 2026, down from 29.7% and 25.2% respectively a year earlier.
• · Dollar General accounted for 15.4% of sales and 36.0% of accounts receivable as of April 17, 2026, up from 14.1% and 24.2% respectively a year earlier.
• · Cash used in operating activities improved to $1.8M for the 24 weeks ended April 17, 2026, from $5.4M in the prior-year period.
• · Capital expenditures were $0.5M for the 24 weeks ended April 17, 2026, down from $1.6M in the prior-year period.
• · The company had no preferred stock issued or outstanding.

01-06-2026

Idaho Copper Corp (COPR) reported a net loss of $1,511,930 for the three months ended April 30, 2026, more than doubling from a $682,888 loss in the same period last year, driven by a 138% surge in operating expenses to $1,340,324. The company remains pre-revenue with zero revenue in both periods. Cash increased sharply to $164,216 from $24,274 at January 31, 2026, primarily due to $1,255,000 in proceeds from convertible notes, but total liabilities rose to $7,189,279 from $6,646,351, and the accumulated deficit widened to $41,729,836.

• · Operating cash flow used was $855,058 in Q1 2026, compared to $225,967 in Q1 2025, a 278% increase in cash burn.
• · Net cash provided by financing activities was $995,000 in Q1 2026, up from $133,000 in Q1 2025.
• · Interest expense rose to $134,805 in Q1 2026 from $119,750 in Q1 2025.
• · Amortization of debt discount was $36,801 in Q1 2026; none in Q1 2025.
• · Basic and diluted net loss per share was $0.11 in Q1 2026 vs $0.05 in Q1 2025.
• · Weighted average common shares outstanding increased to 13,941,951 in Q1 2026 from 13,099,967 in Q1 2025.
• · Stockholders' deficit worsened to $6,718,355 as of April 30, 2026 from $6,454,335 as of January 31, 2026.
• · Convertible notes payable, net of discounts, stood at $610,947 as of April 30, 2026; none at January 31, 2026.
• · Accrued interest, current portion increased to $1,771,234 from $1,681,926.
• · Bond liabilities, current portion decreased to $1,541,000 from $1,791,000.
• · Accounts payable and accrued expenses rose to $712,420 from $478,652.
• · Notes payable to related party increased to $309,000 from $209,000.
• · Deferred offering costs of $133,082 were recorded as of April 30, 2026; none at January 31, 2026.

01-06-2026

Science Applications International Corp (SAIC) reported a robust first quarter for fiscal 2026, with net income surging 69% to $115M from $68M in the prior-year quarter, driven by strong revenue growth and improved operating margins. Revenue rose 1.5% to $1,906M, while operating income jumped 48% to $179M, leading to diluted EPS of $2.61 versus $1.42. However, the company continued aggressive share repurchases, spending $176M on stock buybacks, which reduced shares outstanding from 47.6M to 43.7M, and cash and cash equivalents fell 40% to $109M due to financing outflows.

• · Interest expense increased to $33M from $30M, up 10% YoY.
• · Other operating income improved to $13M income vs $1M expense in prior year, mainly due to gains on sales of investments ($12M).
• · Receivables (net) increased to $962M from $853M, a 12.8% sequential rise.
• · Accounts payable surged to $634M from $500M, up 26.8% sequentially.
• · Stock-based compensation expense declined to $13M from $15M.
• · Depreciation and amortization increased to $40M from $36M.
• · Debt (current portion) rose to $26M from $19M sequentially; total debt was $2,486M ($2,460M non-current + $26M current), slightly down from $2,487M at year-end.
• · Dividends remained steady at $0.37 per share.
• · Total stockholders' equity fell to $1,423M from $1,500M due to share repurchases and dividends.

01-06-2026

NaturalShrimp Inc. reports a net loss of $3.9M for the six months ended September 30, 2024, with net revenue of only $21,501 against $3.2M in total operating expenses. As of September 30, 2025, the company is in liquidation, reporting net liabilities in liquidation of $8.88M, a worsening from $8.79M at March 31, 2025. Cash decreased from $115,525 to $43,330 over the period, highlighting severe liquidity constraints.

• · Net revenue of only $21,501 on sales of $106,991 (80% cost of sales) indicates severe margin compression.
• · Total operating expenses ($3.24M) far exceeded net revenue, driven by general and administrative costs of $1.35M, depreciation of $865K, and amortization of $735K.
• · Other expense items included a $720K charge for change in fair value of restructured notes, partially offset by a $24K gain on warrant liability and a $39K gain on sale of machinery.
• · Cash from operating activities used $1.56M; investing activities provided $118K from sale of equipment; financing activities provided $1.37M, primarily from line of credit ($373K), stock sales ($654K), and preferred share sales ($300K).
• · The company has adopted liquidation basis accounting as of September 30, 2025, with intangible and fixed assets fully de-recognized after transfer to creditors in May 2025.
• · Liabilities in liquidation include $6.8M in accounts payable/accrued expenses (approx. $3.0M to related parties) and $1.18M in notes payable.
• · No additional income is expected through the end of liquidation, and costs through December 31, 2025 are considered immaterial.

01-06-2026

Rapid Line Inc. (RPDL) reported no revenue for the three months ended April 30, 2026, with net loss widening to ($49,299) from ($16,448) in the prior-year period. Total assets decreased to $38,642 from $43,386, while total liabilities grew to $156,441 from $111,886, driven largely by an increase in long-term third-party debt. The company's accumulated deficit deepened to ($285,129) and stockholders' equity fell further into negative territory at ($117,799).

• · Operating cash flow used increased to ($49,494) from ($14,398) in the prior-year period.
• · General and Administrative expenses surged to $49,299 from $16,448, a 200% increase year-over-year.
• · Financing cash flow provided was $46,800 in Q1 FY26 vs. $14,362 in Q1 FY25, driven by related party funding.
• · Deferred tax assets net of valuation allowance remains $0 as the entire net operating loss carryover of ($59,877) at April 30, 2026 is fully reserved.
• · Accumulated amortization on intangible assets was $18,798 at April 30, 2026 vs. $16,748 at January 31, 2026.

01-06-2026

For the three months ended June 30, 2024, Electronic Servitor Publication Network, Inc. reported $0 revenue versus $22,500 in the prior-year quarter. The net loss widened to $178,570 from $100,856, driven by a sharp increase in stock-based compensation ($139,847 vs. $72,395). On a six-month basis, revenue declined 2.2× to $50,000 from $22,500 (though the prior comparison period had only $22,500 for both periods; the six-month revenue drop was 201% higher). The net loss improved slightly to $351,638 from $368,185, but cash on hand fell to just $489, down from $28,431 at year-end 2023, raising significant going-concern risk.

• · Total liabilities of $2.83M exceed total assets of $2,989, resulting in a stockholders' deficit of $2.83M.
• · Accumulated deficit grew to $(7,546,321) as of June 30, 2024, from $(7,194,683) at year-end 2023.
• · The company issued 600,000 shares for services during the six months ended June 30, 2024, with no cash proceeds.
• · Operating activities used $19,942 in cash in H1 2024, compared to $70,859 in H1 2023, an improvement.
• · No cash was generated from financing activities in H1 2024, versus $75,770 in H1 2023.
• · Cash paid for interest and taxes was zero in both periods.

01-06-2026

Agilent Technologies reported strong Q2 FY2026 results with net revenue of $1,835M, up 10.0% YoY from $1,668M, driven by product revenue growth of 10.0% and services revenue growth of 10.0%. Net income surged 57.7% to $339M from $215M, with diluted EPS rising to $1.20 from $0.75. However, operating cash flow declined 16.4% to $545M for the first six months, and the company continued share repurchases and dividends, reducing equity.

• · Q2 FY2026 product revenue was $1,305M (up 10.0% YoY), services and other revenue was $530M (up 10.0% YoY).
• · Income from operations for Q2 was $399M, up 33.0% from $300M in Q2 FY2025.
• · Interest expense decreased to $25M in Q2 from $29M a year ago.
• · Other income (expense), net swung to a gain of $21M from a loss of $25M in Q2 FY2025.
• · Provision for income taxes increased to $69M from $45M in Q2 FY2025.
• · Total assets increased to $13,065M from $12,727M at October 31, 2025.
• · Cash and cash equivalents were $1,807M, up from $1,789M at fiscal year-end.
• · Total debt (short-term + long-term) was $3,355M, essentially unchanged.
• · Share repurchases totaled $217M in H1 FY2026 (plus $3M excise tax), compared to $255M (plus $10M excise tax) in H1 FY2025.
• · Dividends paid were $144M in H1 FY2026, up from $141M in H1 FY2025.
• · Cash flow from operations declined primarily due to a $295M outflow in 'other assets and liabilities' vs. $14M in H1 FY2025.
• · Capital expenditures were $169M in H1 FY2026, down from $211M in H1 FY2025.

01-06-2026

Polomar Health Services reported a dramatic revenue increase to $1,005,519 for Q1 2026 from $4,542 in Q1 2025, driven by the launch of VigorAir. However, the company remains unprofitable with a net loss of $25,377 (improved from a $456,855 loss a year ago), and its accumulated deficit grew to $13,637,645. Additionally, the company faces a major setback as its exclusive distributor ForHumanity has suspended sales of VigorAir and intends to terminate the distribution agreement, casting significant doubt on future revenue sustainability.

• · Cash decreased 33.5% from $132,150 (Dec 31, 2025) to $87,818 (Mar 31, 2026).
• · Accounts receivable increased 76.3% from $96,941 to $170,851.
• · Inventory more than doubled from $93,636 to $208,981.
• · Accounts payable and accrued liabilities rose 61.3% from $386,983 to $624,315.
• · Related party promissory notes decreased 8.8% from $897,660 to $818,952.
• · Operating lease liability decreased from $14,864 to $5,986.
• · Net cash from operating activities was positive $34,376 in Q1 2026 vs negative $45,577 in Q1 2025.
• · Net cash from financing activities was negative $78,708 in Q1 2026 vs positive $168,717 in Q1 2025.
• · The company had a net operating loss carryforward of $13,637,645 as of March 31, 2026.
• · ForHumanity launched test marketing of VigorAir in November 2025 and additional clinical trials were sponsored in December 2025; preliminary results received February 12, 2026, complete results February 28, 2026.
• · ForHumanity has suspended sales of VigorAir and on April 23, 2026, advised Polomar of intent to terminate the distribution agreement.